References
- Deshpand R, Chandra M, Rauthan A (2022) Evolving trends in lung cancer: epidemiology, diagnosis, and management. Indian J Cancer 59(Suppl):S90–S105.
https://doi.org/10.4103/ijc.IJC_52_21 - Frick EA, Kristjansdottir K, Ragnarsdottir S et al. (2024) MicroRNA-190b targets RFWD3 in estrogen receptor-positive breast cancer. Breast Cancer 18:11782234241234771.
https://doi.org/10.1177/11782234241234771 - Gallina I, Hendriks IA, Hoffmann S et al. (2021) The ubiquitin ligase RFWD3 is required for translesion DNA synthesis. Mol Cell 81:442–458.
https://doi.org/10.1016/j.molcel.2020.11.029 - He L, Kang Q, Chan KI et al. (2022) The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer. Front Immunol 13:1093990.
https://doi.org/10.3389/fimmu.2022.1093990 - Jiang P, Xu Z, Wu S et al. (2023) RFWD3 acts as a tumor promotor in the development and progression of bladder cancer. Histol Histopathol 38:917–928.
https://doi.org/10.14670/HH-18-558 - Jia J, Yang Y, Yan T et al. (2020) Down-regulation of RFWD3 inhibits cancer cells proliferation and migration in gastric carcinoma. Gen Physiol Biophys 39:363–371.
https://doi.org/10.4149/gpb_2020009 - Kim EK, Choi EJ (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802:396–405.
https://doi.org/10.1016/j.bbadis.2009.12.009 - Liang RP, Zhang XX, Zhao J et al. (2022) RING finger and WD repeat domain 3 regulates proliferation and metastasis through the Wnt/beta-catenin signalling pathways in hepatocellular carcinoma. World J Gastroenterol 28:3435–3454.
https://doi.org/10.3748/wjg.v28.i27.3435 - Liu W, Ning R, Chen RN et al. (2016) Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells. Mol Carcinog 55:440–457.
https://doi.org/10.1002/mc.22293 - Nooreldeen R, Bach H (2021) Current and future development in lung cancer diagnosis. Int J Mol Sci 22:8661.
https://doi.org/10.3390/ijms22168661 - Pan Z, Wang K, Wang X et al. (2022) Cholesterol promotes EGFRTKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRalpha re-expression. Mol Cancer 21:77.
https://doi.org/10.1186/s12943-022-01547-3 - Petruzelka L, Spacek J, Krizova L (2021) Future of lung cancer treatment. Klin Onkol 34(Suppl. 1):71–81.
https://doi.org/10.48095/ccko2021S71 - Taylor SJ, Hollis RL, Gourley C et al. (2024) RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancer. Front Oncol 14:1389472.
https://doi.org/10.3389/fonc.2024.1389472 - Thai AA, Solomon BJ, Sequist LV et al. (2021) Lung cancer. Lancet 398:535–554.
https://doi.org/10.1016/S0140-6736(21)00312-3 - Tong X, Tang R, Xiao M et al. (2022) Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol 15:174.
https://doi.org/10.1186/s13045-022-01392-3 - Xu F, Xiao Z, Fan L et al. (2021) RFWD3 participates in the occurrence and development of colorectal cancer via E2F1 transcriptional regulation of BIRC5. Front Cell Dev Biol 9:675356.
https://doi.org/10.3389/fcell.2021.675356 - Zhang Y, Zhao X, Zhou Y et al. (2020) Identification of an E3 ligase-encoding gene RFWD3 in non-small cell lung cancer. Front Med 14:318–326.
https://doi.org/10.1007/s11684-019-0708-6